Clinical evaluation of the foam containing heparinoid in patients with asteatosis

Objective: To evaluate the efcacy and safety of a heparinoid foam (hereinafter, the foam) in patients with asteatosis, a heparinoid soft ointment (Hirudoid Soft Ointment 0.3%, hereinafter, the soft ointment) was switched to the foam, and the subjective impressions of both preparations were surveyed. Method: In a multi-center, uncontrolled, open-label study, the soft ointment was applied to patients with asteatosis for 2 weeks. Thereafter, the foam was applied for 2 weeks. Whether the efcacy of the soft ointment was maintained after switching to the foam was examined by investigators, and the skin symptom score was assessed Safety was conrmed based on adverse events and laboratory test values. Patients'impressions of the study drug were surveyed with a patient questionnaire. Results: Sixty patients were enrolled in the study. The study drug was administered to all patients, and they all completed the study without discontinuation. The effects of the two-week application of the soft ointment were maintained after switching to the foam for all patients, excluding one patient with missing data. The skin symptom score improved over time. Switching to the foam neither increased the incidence of adverse events nor affected the laboratory test values. The results of the patient questionnaire indicated that the foam was superior in that it spread easily and was not sticky. Conclusion: The efcacy of the foam was conrmed as the effects of the soft ointment were maintained after switching to the foam. There were no safety issues associated with the foam. The results of the patient questionnaire also suggested the foam to be a new option for patients who prefer a moisturizer that spreads easily and is not sticky.